Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | SVP, Global Government Affairs | February 27, 2018 | March 01, 2018 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | October 05, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date February 27, 2018 · Filed March 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 49,140 |
Ending reported balance
After 2018-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-27 · Sale · Disposed 244 · Balance 49,594 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Row 2 · 2018-02-28 · Sale · Disposed 454 · Balance 49,140 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
Wave Life Sciences, Inc.
Report date October 05, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,630 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 10,700 · Balance 55,630 F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2036-10-05 | Direct | 64,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 64,000 · Balance 64,000 F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantStock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001193125-26-417231 · ownership.xml · derivative · entry 2 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-10-05 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| October 05, 2026 Filed Oct 8, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantCommon Stock | 10,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-417231 · ownership.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,630 F1 · shares: The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001193125-26-349963 · ownership.xml · derivative · entry 3 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,000 shares Expires 2026-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleCommon Stock | 7,000 | $6.01 | $42,070.00 |
DisclosureSEC source: 0001193125-26-349963 · ownership.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,930 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. Read SEC document |
| August 11, 2026 Filed Aug 14, 2026 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionCommon Stock | 7,000 | $5.97 | $41,790.00 |
DisclosureSEC source: 0001193125-26-349963 · ownership.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001193125-25-314741 · ownership.xml · derivative · entry 5 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Ordinary Shares · 14,000 shares Expires 2026-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,000 | $14.00 | $98,000.00 |
DisclosureSEC source: 0001193125-25-314741 · ownership.xml · nonDerivative · entry 4 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,930 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 7,000 | $5.97 | $41,790.00 |
DisclosureSEC source: 0001193125-25-314741 · ownership.xml · nonDerivative · entry 3 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,000 | $13.00 | $91,000.00 |
DisclosureSEC source: 0001193125-25-314741 · ownership.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,930 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 7,000 | $5.97 | $41,790.00 |
DisclosureSEC source: 0001193125-25-314741 · ownership.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 76,200 | $0.00 Strike: $8.11 | $0.00 |
DisclosureSEC source: 0000950170-25-108288 · ownership.xml · derivative · entry 2 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,200 Underlying: Ordinary Shares · 76,200 shares Expires 2030-08-11 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 12,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-108288 · ownership.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,930 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 64,460 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0000950170-24-097284 · ownership.xml · derivative · entry 2 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,460 Underlying: Ordinary Shares · 64,460 shares Expires 2029-08-12 F2 · derivative.exercise_date: The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 32,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-097284 · ownership.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,230 F1 · shares: The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026. Read SEC document |
| August 07, 2023 Filed Aug 10, 2023 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000899243-23-017914 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2028-08-07 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024. Read SEC document |
| August 15, 2022 Filed Aug 18, 2022 00:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000899243-22-029097 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-033531 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2026-08-16 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2022 annual general meeting or August 16, 2022. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:33 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023088 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 22:46 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023034 · doc4.xml · derivative · entry 1 Wagner Heidi L · CIK 0001655029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 454 | $118.61 | $53,848.94 |
DisclosureSEC source: 0000899866-18-000047 · wf-form4_151994308448663.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,140 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 244 | $120.72 | $29,455.68 |
DisclosureSEC source: 0000899866-18-000047 · wf-form4_151994308448663.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,594 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 19:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,774 | $116.31 | $206,333.94 |
DisclosureSEC source: 0000899866-18-000041 · wf-form4_151813543967661.xml · nonDerivative · entry 3 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,838 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000041 · wf-form4_151813543967661.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,612 F2 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 4,400 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 14,577 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000041 · wf-form4_151813543967661.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,212 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 14,577 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 18:36 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 655 | $117.26 | $76,805.30 |
DisclosureSEC source: 0000899866-18-000016 · wf-form4_151804654651208.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,635 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 120 | $140.00 | $16,800.00 |
DisclosureSEC source: 0000899866-17-000170 · wf-form4_150715234025644.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,290 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 19:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 156 | $132.50 | $20,670.00 |
DisclosureSEC source: 0000899866-17-000054 · wf-form4_148841545911470.xml · nonDerivative · entry 3 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,010 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 8,700 | $0.00 Strike: $131.25 | $0.00 |
DisclosureSEC source: 0000899866-17-000054 · wf-form4_148841545911470.xml · derivative · entry 5 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Common Stock, par value $.0001 per share · 8,700 shares Expires 2027-02-28 F5 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000054 · wf-form4_148841545911470.xml · nonDerivative · entry 4 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,410 F4 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 480 | $131.70 | $63,216.00 |
DisclosureSEC source: 0000899866-17-000054 · wf-form4_148841545911470.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 19:44 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 358 | $131.20 | $46,969.60 |
DisclosureSEC source: 0000899866-17-000054 · wf-form4_148841545911470.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,646 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 16:38 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 222 | $128.09 | $28,435.98 |
DisclosureSEC source: 0000899866-17-000024 · wf-form4_148658992215835.xml · nonDerivative · entry 3 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,004 F4 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.00 - $128.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:38 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 15 | $126.04 | $1,890.60 |
DisclosureSEC source: 0000899866-17-000024 · wf-form4_148658992215835.xml · nonDerivative · entry 2 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,226 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:38 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,695 | $125.69 | $213,044.55 |
DisclosureSEC source: 0000899866-17-000024 · wf-form4_148658992215835.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,241 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 18:00 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 59 | $115.10 | $6,790.90 |
DisclosureSEC source: 0000899866-16-000383 · wf-form4_147933718744997.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,936 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 120 | $122.41 | $14,689.20 |
DisclosureSEC source: 0000899866-16-000364 · wf-form4_147570272539300.xml · nonDerivative · entry 1 Wagner Heidi L · CIK 0001655029 · SVP, Global Government Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,995 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $122.00 - $122.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.